Comment from Omega Laboratories, Inc.

Summary: Omega Laboratories, Inc. supports the proposed FDA exemption for certain Class II clinical toxicology test system devices, arguing that workplace drug testing is a forensic rather than a clinical diagnostic process. They advocate for a regulatory framework that recognizes existing forensic quality systems (like CAP and ISO) to avoid duplicative and costly federal certification regimes.